To assess the tolerability and efficacy of a nasal spray formulation containing 0.2 % sodium hyaluronate and 3 % tobramycin compared to a control formulation containing 0.2 % sodium hyaluronate alone in the treatment of bacterial rhinosinusitis in patients with CF.